Skip to content

Author

C. Vlachopoulos

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Survival Outcomes in Transthyretin Cardiac Amyloidosis in the Tafamidis Era: Real-World Evidence from Greece

Background: Diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM) have increased in recent years, with a growing proportion of patients being identified at earlier disease stages. However, temporal trends in ATTR-CM diagnosis and survival during the tafamidis era in the Greek population remain largely unknown. Me...

F. Kourti, A. Antonopoulos, V. Kytinos et al. · 0 citations
Review Open access Sep 2026

Global prevalence and clinical implications of coronary artery dominance: A meta-analysis.

BACKGROUND Coronary artery dominance (CD) influences myocardial perfusion, collateral vessel development, and cardiovascular outcomes. However, reported prevalence estimates vary across populations and study methodologies. This systematic review and meta-analysis aimed to estimate the global prevalence of CD variations...

G. Triantafyllou, Ioannis Paschopoulos, M. Piagkou et al. · 0 citations
Open access Sep 2026

LDL-C Target Attainment and Treatment Gaps Six Months After Acute Coronary Syndrome: insights from the CALLINICUS-Hellas registry.

BACKGROUND Low-density lipoprotein cholesterol (LDL-C) reduction is the cornerstone of secondary prevention after acute coronary syndrome (ACS). Despite potent lipid-lowering therapies (LLTs), a therapeutic gap persists. We aimed to evaluate LDL-C target attainment according to the 2019 ESC/EAS guidelines, identify pre...

L. Rallidis, D. Tsamoulis, Despoina-Rafailia Benetou et al. · 0 citations
Aug 2026

Prevalence and evolution of heart failure in patients with type 2 diabetes mellitus at high cardiovascular risk (HF-LANDMARK study).

The low prevalence of symptomatic HF and low rate of HF-progression likely reflect effective monitoring and intervention at preclinical HF stages, and the substantial healthcare-burden highlights an unmet need regarding implementation of HF preventive management strategies in patients with T2D.

C. Georgiou, V. Bistola, A. Karavidas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.